Chaguan | Globalisation under quarantine

The covid-19 virus is teaching the world hard lessons about China-only supply chains



TNTIL ABOUT the third week of January, only a few pharmaceutical executives, drug-safety inspectors and dogged China hawks cared that a large share of the world's supply of antibiotics d<mark>epends on a handful of Chinese factorie</mark>s. These include a cluster in Inner Mongolia, a northern province of windswept deserts, grasslands and unlovely industrial towns. Then came the covid-19 outbreak, and quarantine controls that locked down factories, ports and whole cities across China.

Chinese leaders insist that they are well on the way to conquering the virus, allowing them to reopen "leading enterprises and key links with important influence" in global supply chains. A victory over the novel coronavirus will once again demonstrate "the notable advantages of leadership by the Communist Party of China", President Xi Jinping told 170,000 officials by video-conference on February 23rd. But even if all those boasts come true, foreign governments and business bosses will not quickly forget a frightening lesson: for some vital products, they depend on one country.

Where once only a few specialists worried about the market share enjoyed by the industrial chemists of Hohhot or Shijiazhuang, China's dominance of the active pharmaceutical ingredient (API) sector is now the subject of hard questions in Washington's corridors of power and the chancelleries of Europe. Ending the world's dependence on Chinese APIS would not be a technical challenge. China has not been dominant for long. America's last penicillin fermenter closed in 2004, as clusters of Chinese factories, many state-owned or subsidised, offered efficiencies that foreign rivals could not match. Rather, change would involve upending well-established political and economic theories, starting with the wisdom of allowing private companies to seek out the best-value goods, with little heed paid to their origin.

There is much speculation about whether covid-19 will accelerate trends in America and other Western countries to decouple from China. In truth, a rush to diversify in certain sectors is more likely, and even such a hedging of bets would build on trends that have been visible for some time.

The us-China Economic and Security Review Commission, a congressional body, held hearings in July 2019 on threats and opportunities created by China's medical industries. The tone quick-

ly veered towards the doomy. A senior Pentagon official, Christo pher Priest, declared that "the national-security risks of increase Chinese dominance of the global API market cannot be overstat ed." He invited the hearing to imagine China interrupting supplie of irreplaceable drugs, such as those that protect troops against an thrax. Another witness, Benjamin Shobert, a health-care strategis at Microsoft, noted that mutual dependency was once seen as reason to believe that Sino-American relations were stable an safe. But in an age of rising distrust, if those same calculated de pendencies were to become a source of fear, then "much of wha has supported the modern era of globalisation is no longer valid.

For implacable China hawks like Peter Navarro, who advise President Donald Trump on trade, the covid-19 crisis is a tolo you-so moment. On February 23rd Mr Navarro told Fox Business, television channel, that America had outsourced "far too much" its supply chain for essential medicines. "We have got to get it bac onshore," he said. Mr Navarro, an economic nationalist and voc tariff advocate, is little loved by America's trade partners. Yet h talk of nations needing to control certain forms of production finds an echo in rich-world capitals.

Joerg Wuttke, the president of the European Union Chamber Commerce in China, says China's dominance in sectors like pha maceuticals and pesticides is a topic of concern when he visits of ficials in Berlin, Brussels and elsewhere. It does not help that Ch na has shown itself willing to use trade to bully other countri during political disputes, as when it denied the export of ra earths to Japan in 2012. He does not expect firms to leave China a together, because it drives global growth in so many sectors. B Mr Wuttke expects the epidemic to intensify European discu sions about industrial policy. "The globalisation of putting ever thing where production is the most efficient, that is over."

James McGregor, a China veteran who heads the Chinese ope ations of APCO, an American consultancy, watched business putting ever more eggs in the China basket for a decade. Hit by r ing labour costs, trade tensions and now the virus, compani have concluded that they need to diversify-though many struggling to find countries with China's infrastructure and ada able labour force. Against that, some firms that are in China to s to China are expanding production there, in part to avoid the t certainty of tariffs. The most capable high-tech companies China as "the market of the future" for such promising industr as autonomous vehicles, robotics and the internet of things. Th may be rewarded for their faith. "We are going to see the Chine government be extraordinarily nice to companies once this vi is over," suggests Mr McGregor.

Foreign trade without foreigners

One visible impact of the virus may be to speed changes at the of firms. Multinationals have increasingly appointed Chinese ecutives (often Western-educated) to run their China operation The epidemic may accelerate departures among the foreign who remain. Air pollution has already driven many away. So old-timers feel less welcome in a China taking a nationalist, thoritarian turn. Now they are living alone after evacuating the families, or in temporary exile abroad scrambling to find child school places in home countries they barely know. "A lot of contemporaries don't need much of a push" to leave, says a lo time China hand. Even if covid-19 burns out soon, it has clari how the world is growing warier of China. Few firms can affor leave completely. But an emotional decoupling is under way.